Establishment and validation of a predictive nomogram model for non-small cell lung cancer patients with chronic hepatitis B viral infection

Abstract

BackgroundThis study aimed to establish an effective predictive nomogram for non-small cell lung cancer (NSCLC) patients with chronic hepatitis B viral (HBV) infection.MethodsThe nomogram was based on a retrospective study of 230 NSCLC patients with chronic HBV infection. The predictive accuracy and discriminative ability of the nomogram were determined by a concordance index (C-index), calibration plot and decision curve analysis and were compared with the current tumor, node, and metastasis (TNM) staging system.ResultsIndependent factors derived from Kaplan–Meier analysis of the primary cohort to predict overall survival (OS) were all assembled into a Cox proportional hazards regression model to build the nomogram model. The final model included age, tumor size, TNM stage, treatment, apolipoprotein A-I, apolipoprotein B, glutamyl transpeptidase and lactate dehydrogenase. The calibration curve for the probability of OS showed that the nomogram-based predictions were in good agreement with the actual observations. The C-index of the model for predicting OS had a superior discrimination power compared with the TNM staging system [0.780 (95% CI 0.733–0.827) vs. 0.693 (95% CI 0.640–0.746), P < 0.01], and the decision curve analyses showed that the nomogram model had a higher overall net benefit than did the TNM stage. Based on the total prognostic scores (TPS) of the nomogram, we further subdivided the study cohort into three groups: low risk (TPS ≤ 13.5), intermediate risk (13.5 < TPS ≤ 20.0) and high risk (TPS > 20.0).ConclusionThe proposed nomogram model resulted in more accurate prognostic prediction for NSCLC patients with chronic HBV infection.

Association Between Pretreatment Serum Apolipoprotein A1 and Prognosis of Solid Tumors in Chinese Population: A Systematic Review and Meta-Analysis

“…The included studies originated from Guangdong [27, 29-36, 39], Beijing [28], and Shanghai [37, 38]. A total of 8052 patients diagnosed with several kinds of cancers were including.…”

“…These treatments included surgery [27, 28, 31, 32, 34-37], chemotherapy [33, 39], radiotherapy [30], and mixed treatment [29, 38]. The HRs and their 95% CIs in 11 cohorts were directly extracted from multivariate analyses, while those of the other cohorts were obtained from univariate analyses [27, 29, 31]. All cohort studies were of high quality and had seven scores or more in the quality criteria.…”

“…The outcomes of OS were reported in all 14 cohorts, and the end points of DFS were presented in 4 cohorts [30-32, 36]. Nine cohorts recruited patients with all disease stages (stage I – IV) [27, 29, 30, 32, 34-37], three cohorts included patients with advanced stage (including stage IV [33, 39], and stage IIB – IV [38]), one cohort contained patients with stage I – III [31], and the other one reported the data of patient with stage Tis – T1 [28]. The median follow-up time ranged from 20.3 months to 89 months, and even five studies did not report it.…”

“…A total of 8052 patients diagnosed with several kinds of cancers were including. These cancers included gastric cancer (GC) [27], bladder cancer [28], non small cell lung cancer (NSCLC) [29, 38], nasopharyngeal carcinoma (NPC) [30, 39], breast cancer [31, 32], colorectal cancer (CRC) [33], upper tract urothelial carcinoma (UTUC) [34], esophageal squamous cell cancer (ESCC) [35], renal cell carcinoma (RCC) [36], and hepatocellular carcinoma (HCC) [37]. Eleven studies were published in English [27-33, 35-37, 39], whereas the other two studies were in Chinese [34, 39].…”

A convenient clinical nomogram for predicting the cancer-specific survival of individual patients with small-intestine adenocarcinoma

“…In addition, several studies have shown that a nomogram is superior to the AJCC TNM staging system in predicting the survival of cancer patients [14][15][16][17]. However, few studies have used nomograms to predict the prognosis of patients with small-intestine adenocarcinoma.…”